» Articles » PMID: 25368412

Epitope Identification from Fixed-complexity Random-sequence Peptide Microarrays

Overview
Date 2014 Nov 5
PMID 25368412
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Antibodies play an important role in modern science and medicine. They are essential in many biological assays and have emerged as an important class of therapeutics. Unfortunately, current methods for mapping antibody epitopes require costly synthesis or enrichment steps, and no low-cost universal platform exists. In order to address this, we tested a random-sequence peptide microarray consisting of over 330,000 unique peptide sequences sampling 83% of all possible tetramers and 27% of pentamers. It is a single, unbiased platform that can be used in many different types of tests, it does not rely on informatic selection of peptides for a particular proteome, and it does not require iterative rounds of selection. In order to optimize the platform, we developed an algorithm that considers the significance of k-length peptide subsequences (k-mers) within selected peptides that come from the microarray. We tested eight monoclonal antibodies and seven infectious disease cohorts. The method correctly identified five of the eight monoclonal epitopes and identified both reported and unreported epitope candidates in the infectious disease cohorts. This algorithm could greatly enhance the utility of random-sequence peptide microarrays by enabling rapid epitope mapping and antigen identification.

Citing Articles

A survey of k-mer methods and applications in bioinformatics.

Moeckel C, Mareboina M, Konnaris M, Chan C, Mouratidis I, Montgomery A Comput Struct Biotechnol J. 2024; 23:2289-2303.

PMID: 38840832 PMC: 11152613. DOI: 10.1016/j.csbj.2024.05.025.


Highly heterogenous humoral immune response in Lyme disease patients revealed by broad machine learning-assisted antibody binding profiling with random peptide arrays.

Kelbauskas L, Legutki J, Woodbury N Front Immunol. 2024; 15:1335446.

PMID: 38318184 PMC: 10838964. DOI: 10.3389/fimmu.2024.1335446.


Modeling the sequence dependence of differential antibody binding in the immune response to infectious disease.

Chowdhury R, Taguchi A, Kelbauskas L, Stafford P, Diehnelt C, Zhao Z PLoS Comput Biol. 2023; 19(6):e1010773.

PMID: 37339137 PMC: 10313026. DOI: 10.1371/journal.pcbi.1010773.


APRANK: Computational Prioritization of Antigenic Proteins and Peptides From Complete Pathogen Proteomes.

Ricci A, Brunner M, Ramoa D, Carmona S, Nielsen M, Aguero F Front Immunol. 2021; 12:702552.

PMID: 34335615 PMC: 8320365. DOI: 10.3389/fimmu.2021.702552.


Protein-Based Immunome Wide Association Studies (PIWAS) for the Discovery of Significant Disease-Associated Antigens.

Haynes W, Kamath K, Waitz R, Daugherty P, Shon J Front Immunol. 2021; 12:625311.

PMID: 33986742 PMC: 8110919. DOI: 10.3389/fimmu.2021.625311.


References
1.
Wagner B, Freer H, Rollins A, Garcia-Tapia D, Erb H, Earnhart C . Antibodies to Borrelia burgdorferi OspA, OspC, OspF, and C6 antigens as markers for early and late infection in dogs. Clin Vaccine Immunol. 2012; 19(4):527-35. PMC: 3318275. DOI: 10.1128/CVI.05653-11. View

2.
Sykes K, Legutki J, Stafford P . Immunosignaturing: a critical review. Trends Biotechnol. 2012; 31(1):45-51. DOI: 10.1016/j.tibtech.2012.10.012. View

3.
Fack F, Song D, Queitsch I, Petersen G, Bautz E . Epitope mapping by phage display: random versus gene-fragment libraries. J Immunol Methods. 1997; 206(1-2):43-52. DOI: 10.1016/s0022-1759(97)00083-5. View

4.
Stafford P, Cichacz Z, Woodbury N, Johnston S . Immunosignature system for diagnosis of cancer. Proc Natl Acad Sci U S A. 2014; 111(30):E3072-80. PMC: 4121770. DOI: 10.1073/pnas.1409432111. View

5.
Reichert J, Valge-Archer V . Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov. 2007; 6(5):349-56. DOI: 10.1038/nrd2241. View